ReviewJournal of ovarian research2026
Dual regulation of PINK1/PARKIN-mediated mitochondrial autophagy in ovarian cancer progression and drug resistance: mechanisms and therapeutic potentials.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ovarian cancer (OC) is a common primary female malignancy globally. It is characterized by a high rate of confirmed diagnosis at an advanced stage (around 70%), abdominal and distant metastases at initial diagnosis, and relatively lower average 5-year survival rate worldwide (< 30%). This undoubtedly greatly increases the difficulty and complexity of the treatment. The therapeutic effect of OC is primarily compromised by the mechanism of chemotherapy resistance, which is complex and has not been fully elucidated. Beyond producing negative impact on the effectiveness of existing treatment strategies, the resistance of cancer cells to chemotherapeutic agents may also prompt the medical community to constantly explore new treatment approaches. Therefore, in order to develop more effective treatment plans, it highlights the importance and necessity of achieving a thorough understanding of the pathogenesis of OC and the mechanism of chemotherapy resistance. Currently, mitophagy, an intracellular self-degradation process, has been documented to be pivotal in the development of OC and in chemotherapy resistance. It functions to maintain the stability of the intracellular environment through the autophagy mechanism, regulate cellular energy metabolism, and participate in immune responses, supporting its potential of inhibiting tumor growth theoretically. In particular, the PINK1/PARKIN pathway demonstrates a unique bidirectional regulatory effect in tumor growth regulation and chemotherapy resistance reversal. Its dynamic regulatory mechanism in platinum-based resistance of OC has revealed potential therapeutic targets. Accordingly, with emphasis on the bidirectional regulatory role of the PINK1/PARKIN signaling pathway-mediated mitophagy in inhibiting the growth of OC and reversing chemotherapy resistance, this study aimed to integrate the latest research results, and provide innovative treatment strategies and ideas for OC treatment and chemotherapy efficacy optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.